開催日時 & 会場

• 2024年10月16日, 17:00-18:00
• 会場: Seminar Room 103/107, Faculty of Medicine Bldg. A 1F (Bldg. No 5)
• 対面型, 参加無料
• 主催者 : がん免疫総合研究センター (CCII)

演者

Dr. Nicholas P Restifo

MD, Advisory Board
IMEL Biotherapeutics

概要

T cell exhaustion and accelerated aging is a hallmark of most tumor-specific T cells, a critical component of the immune response to tumors. Tumor-specific T cells may accumulate at tumor sites because they experience migratory arrest and remain in proximity to tumor cells but are unable to exert effective anti-tumor activity. Despite this pervasive exhaustion, TIL can trigger objective clinical responses in a broad range of malignancies, including breast, colon, bile duct, lung, and HPV-associated cancers. I will review the cell intrinsic molecular and functional correlates of clinically effective TIL. A deeper understanding of the qualities of clinically effective TIL is guiding efforts to rejuvenate and re-functionalize these cells, which includes epigenetic interventions and repair or replacement of dysfunctional mitochondrial within TIL for use in treatment-refractory malignancies.